Anoat Therapeutics develops an innovative, disease-modifying approach in Cystic Fibrosis.
Anoat Therapeutics has raised $2.2M in total funding. The most recent round was Seed. The last funding was announced in June 2023.
Anoat Therapeutics's investors include AdBio partners.
Anoat Therapeutics is headquartered in Paris, France.
Anoat Therapeutics develops an innovative, disease-modifying approach in Cystic Fibrosis.
Anoat Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anoat Therapeutics — Funding & Investors." VCBacked, June 19, 2023, https://www.vcbacked.co/company/anoat-therapeutics. Accessed November 13, 2026.
VCBacked. (2023). Anoat Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/anoat-therapeutics
{{cite web |title=Anoat Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/anoat-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Anoat Therapeutics? Request a listing update